# 1. Financial Performance ## A. Key Figures * Gross Margin: 42% FY '26 (+107 bps) · 42.3% Q4 ## B. Revenue & Profitability * **Record Earnings Amid Headwinds:** Achieved highest-ever profitability despite adverse agro-climatic conditions and a decline in animal nutrition distribution. * **Core Agrochemical Strength:** While headline growth was modest, the core agrochemical segment saw robust volume growth of **5%-6%**, with pricing remaining largely stable. * **Strategic Demand Alignment:** Q4 performance was driven by a shift toward supplying material based on actual ground-level demand forecasts rather than short-term channel loading. * **Product Mix Shift:** Domestic branded formulations increased to **81%** of revenue, signaling a successful transition toward higher-margin segments. ## C. Margin Expansion * **Specialty Product Tailwinds:** Record-level margins were supported by an improved specialty mix, with branded products now comprising **40%** of exports. * **Price Realization Strategy:** Management is actively passing on cost escalations to maintain margin neutrality; better price realization has been observed since late March. * **Royalty & Exceptional Items:** Profitability remained resilient despite a **₹16.1 Cr** exceptional labor code charge; new royalty arrangements are capped at a negligible **₹2 Cr** annually. ## D. Working Capital & Capital Allocation * **Inventory & Receivables:** Working capital cycle lengthened to 103 days due to deliberate seasonal inventory buildup, though receivable days improved significantly to **83 days**. * **Self-Funded Growth:** All upcoming CAPEX will be financed through internal accruals; net worth grew to **₹3,394 Cr** solely via retained earnings. * **Structural Currency Hedge:** The business maintains a "self-hedging" model with balanced exports and imports of **$70M–$80M**, neutralizing rupee volatility. --- # 2. Product & Segment Performance ## A. Key Figures * **Biologicals Revenue Mix:** **8% to 10%** of total revenue * **Animal Nutrition Margins:** **4% to 5%** expected profitability ## B. Herbicide Performance * **Volume-Led Momentum:** Robust double-digit annual growth was primarily driven by volume gains rather than pricing, as price hikes were only implemented in **late March**. * **Portfolio Drivers:** Strong performance anchored by the success of **flumioxazin** (soybean), the **Lentigo** launch (rice), and flagship **Mera 71** (glyphosate). * **High Channel Integrity:** Management reported zero product returns for the herbicide category, indicating healthy underlying market consumption. ## C. Specialty & Custom Synthesis * **Structural Revenue Quality:** A pipeline of **3 to 4 molecules** from the SCC global portfolio is expected to enhance revenue quality over a **3 to 5-year** horizon. * **CRAMS Contribution:** Custom synthesis (CSM) sales to the parent company currently contribute between **₹100 Cr and ₹150 Cr** depending on global volumes. * **Resilient Insecticides:** Despite adverse monsoon conditions hampering application, insecticide consumption remained stable. ## D. Biologicals & Animal Nutrition * **Biologicals Leadership:** Current revenue contribution is nearly double the industry average; management anticipates meaningful share expansion starting in **FY27**. * **Strategic Reversal in Animal Nutrition:** Distribution will restart immediately to mitigate global supply chain volatility, despite the segment's commodity-like margins. * **Geopolitical Pricing Impact:** Animal nutrition products are experiencing significant price volatility and increases due to current geopolitical factors. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Dahej Capex Project:** **₹150 Cr** Initial investment (Commercialization: ~2 years) ## B. Dahej Expansion & Strategy * **Phased Capacity Expansion:** Initiated a multi-year capex program at Dahej with a strategy to announce sequential projects of **similar investment quantum** approximately every year. * **Vertical Integration:** The current investment focuses on a high-level backward-integrated herbicide intermediate, enhancing supply chain control. * **Multi-Location Growth:** Manufacturing footprint is scaling across **Bhavnagar, Tarapur, and Dahej** while adhering to strict financial discipline. ## C. Global Hub Strategy * **Strategic Elevation:** Sumitomo Chemical Japan has integrated India into its **top-tier global discovery pipeline**, aligning it with major markets like North America and Europe for early-stage molecule testing. * **Manufacturing Hub Status:** India is being positioned as a global hub for agro and life sciences, with Dahej specifically designated to serve international requirements. * **Supply Chain Flexibility:** Parent company has granted autonomy to source technicals for **2 to 3 specific products** from third-party vendors, easing internal supply constraints. ## D. Capex Timelines & Outlook * **Execution Track Record:** All proprietary and patented product infrastructure projects remain on schedule, with incremental revenue from ongoing works expected to start next year. * **Long-term Pipeline:** Management is conducting techno-commercial feasibility for a decade-long investment pipeline, maintaining a **minimum 2-year lead time** for any new project commercialization. * **Future Readiness:** High technical confidence in upcoming agri-intermediate projects currently undergoing feasibility studies to sustain growth momentum. --- # 4. Technology & Innovation ## A. Parent Pipeline & Strategic Agreements * **Royalty Structure Pivot:** SCIL is transitioning from a zero-royalty model to a **new royalty arrangement** for select products, enabling external procurement of technical goods while retaining access to parent IP and brands. * **Exclusive Market Access:** The company maintains exclusive rights to distribute SCC’s global innovations in India, leveraging parent formulation technologies and trademarks. * **Custom Synthesis Outlook:** Growth in custom synthesis is projected to accelerate from the **next financial year** as current implementation-phase projects come online. * **Commercialization Timeline:** Following the Excalia Max launch, the next wave of molecules is being targeted for commercialization by **FY 2027**. ## B. Semiconductor Chemicals & R&D * **Semiconductor Entry:** Collaborative efforts with Sumitomo Chemical Japan’s ICTM department are underway to commercialize **high-purity semiconductor chemicals**; a formal project announcement is expected shortly. * **R&D Autonomy:** The Indian R&D team has been granted a "free hand" by the parent company to lead technical developments locally without requiring additional Japanese manpower. ## C. Digital Outreach & Operational Tech * **Marketing Innovation:** Significant scaling of digital touch points and campaign precision has been achieved alongside a double-digit reduction in engagement costs. * **Digital Infrastructure:** Operational efficiency is being bolstered by the **Sumitomo Connect** suite, with a new **MDO tracking application** slated for rollout this fiscal year. --- # 5. Supply Chain & Distribution ## A. Inventory & Supply Chain Management * **Strategic Stockpiling:** Deliberate inventory expansion beyond standard cycles served as a hedge against volatile packaging and oil-based raw material costs. * **Channel Integrity:** Distinguished from industry peers by reporting zero herbicide product returns, reflecting a disciplined "margin-over-volume" approach and avoidance of channel dumping. * **Pre-buying Momentum:** Herbicide volumes were bolstered by channel partners securing stock early due to global geopolitical uncertainties and supply concerns. * **Logistics Resilience:** While global container constraints impacted export timing, domestic supply remains robust with no procurement disruptions reported. ## B. Pricing Strategy * **Systematic Cost Pass-through:** Management is protecting margins via a product-by-product pricing strategy rather than blanket increases, successfully passing on freight and naphtha-linked volatility. * **Aggressive Hike Cadence:** Implemented three consecutive price increases between **March and May**, with a potential fourth round slated for **June** to offset persistent inflation. * **Sourcing Flexibility:** A new arrangement with SCC allows the company to waive mandatory technical goods purchases for **2-3 products**, enabling cheaper third-party procurement. * **Brand-Led Pricing:** Price adjustments are being calibrated based on brand equity and popularity, particularly for high-demand products like Glyphosate. ## C. Market Outlook & Engagement * **Demand Generation:** Intensive field exercises during the rabi season have strengthened farmer connectivity, positioning the company for the upcoming kharif cycle. * **Consumption Elasticity:** Management anticipates sustained agrochemical demand despite inflation, as these products represent a minimal portion of total farming input costs. * **Export Uncertainty:** Future international volume growth remains contingent on the stabilization of global logistics and the price sensitivity of overseas customers. --- # 6. Risks & Agrochemical Factors ## A. Key Figures * **Monsoon Forecast:** **92%** of Long Period Average (Below Normal) * Irrigation Coverage: 55% of India's net sown area has access to assured irrigation ## B. Monsoon & Weather * **Climatic Headwinds:** Excessive rainfall from mid-July to October severely damaged key crops (soybean, cotton, groundnut, chilli), impacting insecticide and fungicide demand. * **Segment-Specific Impact:** Continuous rains led to a significant decline in the **Plant Growth Regulator (PGR)** segment, as a poor grape season prevented necessary spraying. * **Strategic Agility:** Management utilizes high-frequency monitoring (weekly/daily) of weather and competitor pricing to make rapid cost-absorption and operational decisions. ## C. Regulatory Constraints * **Biostimulant Recovery:** Industry-wide regulatory hurdles for biostimulants and bio-products (affecting the **Barrix** subsidiary) have largely been resolved as of late 2025. * **Portfolio Resumption:** Following new approvals, sales have resumed for the biological portfolio, including the registration of **Top Grain** from the Sumitomo Biorational portfolio. ## D. Geopolitical Volatility * **Export Dynamics:** Middle East tensions have triggered price increases for certain **technical products**, potentially shifting demand and margin profiles for the export segment. * **Market Normalization:** Pricing sustainability remains tied to conflict duration; a resolution to the war could shift market focus from price protection to volume-based competition. ## E. Input Cost Inflation * **Cost Headwinds:** FY '27 performance is pressured by a **depreciating rupee** and escalating expenses across raw materials, packaging, solvents, and logistics. --- # 7. Guidance & Outlook ## A. Key Figures * Revenue Guidance: ₹110 Cr – ₹130 Cr range for current FY * **New Product Contribution:** **~8%** of total domestic revenue from launches within last 3 years * **Product Pipeline:** **7** new products launched in FY '26 · **1** additional launch pending registration in current FY ## B. FY27 Growth & Market Outlook * **Capacity & Supply Chain:** Operations are currently running at full utilization with zero supply chain bottlenecks heading into the new fiscal year. * **Macro Tailwinds & Risks:** Sector optimism is supported by increased government MSPs, though growth remains sensitive to monsoon patterns, fertilizer availability, and competitive pricing pressures. * **Strategic Priorities:** Management is pivoting toward demand generation and scaling recently launched proprietary/patented technologies to drive volume. * **Capex Impact:** No incremental revenue contribution is expected from new capital expenditure projects within the current financial year. ## C. Leadership Transition * **C-Suite Succession:** **Dr. Suresh Ramachandran** will elevate to Managing Director on **September 1, 2026**, as the current MD transitions to the Chairmanship. * **Board Refresh:** A structured transition is underway with new Independent Director appointments and the retirement of **Mr. Sushil Marfatia**, who moves to an advisory role. * **Institutional Continuity:** A senior management layer of three Vice Presidents has been established to anchor the transition and ensure leadership depth post-September 2026. ## D. New Launches & Innovation * **Portfolio Evolution:** Rapid adoption of new molecules, including **Lentigo** and **Excalia Max**, highlights the successful integration of parent-company (SCC) R&D. * **Upcoming Commercialization:** Following recent registration, the biostimulant **TopGrain** is slated for commercial launch in the upcoming kharif season. * **Lifecycle Management:** SCIL is committed to managing the full lifecycle of proprietary molecules to maintain the strategic confidence of its Japanese parent entity. ## E. Margin Sustainability * **Profitability Resilience:** Management asserts that historical margin profiles are sustainable through a flexible product mix, despite global pricing volatility and geopolitical conflicts. * **Pricing Strategy:** The company is adopting a disciplined approach to cost pass-throughs to protect market share while prioritizing long-term margin stability.